Full Year 2023 Outlook
- Ginkgo is targeting 100 new Cell Programs to the Foundry platform in 2023
- Ginkgo is expecting Total revenue of $245 to $260 million in 2023
- Ginkgo revised its expectation for Cell Engineering revenue to $145 to $160 million in 2023. This guidance excludes the impact of any downstream value share revenue. This revision is driven by an evolution in the typical size and structure of our contracts, including success-based pricing which is impacting the timing of revenue recognition. The flexibility we're able to provide to customers during an ongoing challenging environment, particularly for industrial biotechnology, is a key part of our value proposition.
- While Biosecurity remains an uncertain business, Ginkgo continues to expect Biosecurity revenue in 2023 of at least $100 million, including a mix shift towards emerging product lines that are expected to be more recurring in nature, such as federal and international partnerships supporting pathogen monitoring and biosecurity infrastructure development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.